Market Access & Payers Practice
The market is becoming more challenging - understanding payer needs will enable effective responses to ‘4th and 5th Hurdles’
The First Three: Safety, Efficacy, Quality
- Regulatory requirements that are necessary for product approval but by themselves do not assure maximum access and reimbursement in many markets.
The Fourth: Value
- Demanded by payers and described in the guidelines for economic evaluation of pharmaceuticals that have been developed by NICE and other organizations.
The Fifth: Affordability
- Societal restrictions for patient access to medicines are determined by the ability of a society to pay for expensive modern technology.
GfK Healthcare offers the following:
- Ability to review and recommend on Market Access & Pricing Strategy on a global basis.
- Access to high level payer opinions and stakeholders.
- Payer/Customer Advisory Boards.
- Preparation of business case templates and full range of market access materials e.g. value dossiers.
- Quantitative price research and modelling.
Payers exert a number of supply and demand-side controls:
- National authorities across the G8 implement a series of measures, both controls and incentives to influence supply and demand of pharmaceuticals. Some countries continue to put greater emphasis on supply, e.g. France, although the focus on demand-side has gathered pace in most.
- All countries now recognise that both supply- and demand-side action may be needed in order to control the rate of growth of pharmaceutical expenditure, but obviously, it is more difficult to effectively control the demand side than it is to apply regulatory controls to the supply side with emphasis on price and/or price volume agreements.
- Alongside supply-and-demand-side measures comes the quest for increased efficiency in the resources spent on healthcare, including pharmaceuticals.
- An increasing number of pricing and reimbursement authorities in Europe have intensified their pursuit towards efficient use of resources trough the explicit or implicit use of health economic evaluations.
- It will be therefore be important to interview those personnel responsible for Pricing and reimbursement decisions as well as those involve in advising authorities with health economic evaluations, these Health Technology Appraisal reviewers are increasingly prevalent throughout the countries under evaluation.
